^
    Back
    Association details:
    Biomarker:VTCN1 expression
    Cancer:Breast Cancer
    Drug:emiltatug ledadotin (XMT-1660) (Tubulin inhibitor, B7-H4-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Mol Cancer Ther
    Title:

    Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer

    Published date:
    06/09/2023
    Excerpt:
    In a panel of 28 breast cancer patient-derived xenografts (PDX), XMT-1660 demonstrated activity that correlated with B7-H4 expression.
    DOI:
    https://doi.org/10.1158/1535-7163.MCT-22-0786
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancer Res
    Title:

    Antitumor effect of XMT1660, a B7H4 targeting antibody drug conjugate, in an unselected panel of patient derived xenograft models of breast cancer

    Published date:
    06/15/2022
    Excerpt:
    In this panel of breast patient derived xenograft models, a range of anti-tumor activities has been observed following administration of a single dose of XMT-1660. The relationship between XMT-1660 anti-tumor activity and B7-H4 expression was demonstrated.
    DOI:
    https://doi.org/10.1158/1538-7445.AM2022-1756